Gene therapy for CNS disorders: modalities, delivery and translational challenges
Nature Reviews Neuroscience · 2024-08 · 25 (8) · 553-572
DOI: 10.1038/s41583-024-00829-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nature Reviews Neuroscience, online erschienen am 19.06.2024. Verfasst von Jingjing Gao und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of Massachusetts, Amherst, MA, USA. jgao@umass.edu. Hauptthemen laut MEDLINE: Genetic Therapy, Central Nervous System Diseases. Die Arbeit wurde bisher 98-mal zitiert (Crossref) und nennt 317 Literaturangaben. Gefördert von: NIAMS NIH HHS.
Abstract (Originalsprache)
Gene therapy is emerging as a powerful tool to modulate abnormal gene expression, a hallmark of most CNS disorders. The transformative potentials of recently approved gene therapies for the treatment of spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) and active cerebral adrenoleukodystrophy are encouraging further development of this approach. However, most attempts to translate gene therapy to the clinic have failed to make it to market. There is an urgent need not only to tailor the genes that are targeted to the pathology of interest but to also address delivery challenges and thereby maximize the utility of genetic tools. In this Review, we provide an overview of gene therapy modalities for CNS diseases, emphasizing the interconnectedness of different delivery strategies and routes of administration. Important gaps in understanding that could accelerate the clinical translatability of CNS genetic interventions are addressed, and we present lessons learned from failed clinical trials that may guide the future development of gene therapies for the treatment and management of CNS disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Biomedical Engineering, University of Massachusetts, Amherst, MA, USA. jgao@umass.edu.
- Center for Bioactive Delivery, Institute for Applied Life Sciences, University of Massachusetts, Amherst, MA, USA. jgao@umass.edu.
- Center for Nanomedicine, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, MA, USA.
- Department of Biomedical Engineering, University of Massachusetts, Amherst, MA, USA.
- Marine College, Shandong University, Weihai, China.
- Harvard Medical School, Boston, MA, USA.
ORCID-Profile: Ziting Judy Xia, Dongtak Lee, James N Luo, Jeffrey M Karp, Rudolph Tanzi, Nitin Joshi
Förderung
- NIAMS NIH HHS
Zitieren
APA
Gao, J., Gunasekar, S., Xia, Z. J., Shalin, K., Jiang, C., Chen, H., Lee, D., Lee, S., Pisal, N. D., Luo, J. N., Griciuc, A., Karp, J. M., Tanzi, R., & Joshi, N. (2024). Gene therapy for CNS disorders: modalities, delivery and translational challenges. Nature Reviews Neuroscience, 25(8), 553-572. https://doi.org/10.1038/s41583-024-00829-7
Vancouver
Gao J, Gunasekar S, Xia ZJ, Shalin K, Jiang C, Chen H, et al. Gene therapy for CNS disorders: modalities, delivery and translational challenges. Nature Reviews Neuroscience. 2024;25(8):553-572. doi:10.1038/s41583-024-00829-7
BibTeX
@article{Gao2024,
author = {Gao, Jingjing and Gunasekar, Swetharajan and Xia, Ziting Judy and Shalin, Kiruba and Jiang, Christopher and Chen, Hao and Lee, Dongtak and Lee, Sohyung and Pisal, Nishkal D and Luo, James N and Griciuc, Ana and Karp, Jeffrey M and Tanzi, Rudolph and Joshi, Nitin},
title = {Gene therapy for CNS disorders: modalities, delivery and translational challenges},
journal = {Nature Reviews Neuroscience},
year = {2024},
volume = {25},
number = {8},
pages = {553--572},
doi = {10.1038/s41583-024-00829-7}
}
EUVIMED